Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology - 1 Apr 2020

Liao Xin, Huang Liu, Yu Qianqian, He Siyuan, Li Qianxia, Huang Chao, Yuan Xianglin

Abstract excerpt

PURPOSE: Capecitabine is a widely used 5-fluorouracil oral prodrug. Hand-foot syndrome (HFS), one of the most common adverse events of capecitabine, impacts patients' quality of life seriously. The pathogenesis of HFS remains unclear but was usually considered as a type of inflammation conducted by cyclooxygenase-2 (COX-2). The COX-2/PGES/EP signaling pathway plays an important role in the inflammatory reaction....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Cyclooxygenase 2

Share to Follow-Up Studies

Share to Incidence

Share to Stomach Neoplasms

Source

Identifiers

PMID: 32193619
DOI: 10.1007/s00280-020-04053-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SNPs in the COX-2/PGES/EP signaling pathway are associated with risk of severe capecitabine-induced hand-foot syndrome.PMID 32193619Read ↗

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.Semantic proximity Read ↗

Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYDSemantic proximity Read ↗

Polymorphisms of FGFR Pathway-related Factors and Capecitabine-induced Hand-foot Syndrome in Japanese Patients With Colorectal Cancer.Semantic proximity Read ↗

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer.Semantic proximity Read ↗

Hand-Foot Syndrome in Cancer Patients on Capecitabine: Examining Prevalence, Impacts, and Associated Risk Factors at a Cancer Centre in MalaysiaSemantic proximity Read ↗

Polymorphisms of MTHFR and TYMS predict capecitabine‐induced hand‐foot syndrome in patients with metastatic breast cancerSemantic proximity Read ↗

Spermine-Related DNA Hypermethylation and Elevated Expression of Genes for Collagen Formation are Susceptible Factors for Chemotherapy-Induced Hand-Foot Syndrome in Chinese Colorectal Cancer PatientsSemantic proximity Read ↗

A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.Semantic proximity Read ↗

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.Semantic proximity Read ↗

Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome.Semantic proximity Read ↗

Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.Semantic proximity Read ↗

Association of VEGFA and CCL4L2 polymorphisms with hand-foot skin reaction and survival of regorafenib in Japanese patients with colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.